Last updated: November 4, 2026
Stalevo 150 is the fixed-dose combination of carbidopa 37.5 mg, levodopa 150 mg, and entacapone 200 mg for Parkinson's disease. Novartis commercialized the product, which received U.S. FDA approval in 2003. Its market position has declined because the product has long been exposed to generic competition, levodopa-carbidopa alternatives, and newer Parkinson's therapies. Public filings do not separately report Stalevo 150 revenue, so its financial trajectory must be assessed through product-level regulatory data, generic entry, therapeutic substitution, and Novartis portfolio disclosures rather than a standalone sales series. [1][2]
What is Stalevo 150 and how does it work?
Stalevo 150 combines three active ingredients:
| Component |
Amount per tablet |
Function |
| Carbidopa |
37.5 mg |
Inhibits peripheral levodopa metabolism |
| Levodopa |
150 mg |
Converts to dopamine in the central nervous system |
| Entacapone |
200 mg |
Inhibits catechol-O-methyltransferase and extends levodopa exposure |
The product is used in adults with Parkinson's disease who experience end-of-dose "wearing off" while receiving levodopa and a dopa-decarboxylase inhibitor. Each tablet corresponds to a 150 mg levodopa dose and is one of several Stalevo strengths, ranging from 50 mg to 200 mg of levodopa. [1]
Stalevo 150 is not a biologic and does not have biosimilar exposure. Its principal competitive risk comes from generic fixed-dose combinations, separate carbidopa-levodopa plus entacapone therapy, and alternative formulations such as Rytary extended-release capsules and Inbrija inhaled levodopa.
When did Stalevo 150 lose market exclusivity?
Stalevo 150 lost meaningful U.S. market exclusivity years ago. The product was approved in 2003, and generic versions of carbidopa, levodopa, and entacapone combinations entered the U.S. market after the relevant branded protection periods ended. The FDA Orange Book identifies drug approval and patent-listing information, but it does not provide a current commercial-exclusivity shield for Stalevo 150 comparable to a recently launched branded medicine. [1][3]
| Milestone |
Approximate timing |
Commercial effect |
| U.S. approval of Stalevo |
2003 |
Established branded combination product |
| Initial branded growth |
Mid-2000s |
Adoption for wearing-off patients |
| Loss of core patent exclusivity |
Late 2000s to early 2010s, depending on patent and jurisdiction |
Opened pathway for generic competition |
| Generic carbidopa-levodopa-entacapone competition |
2010s |
Reduced price and volume share for the Novartis brand |
| Mature generic market |
2020s |
Brand demand concentrated in continuity-of-care and payer-specific channels |
Exact patent expiration dates depend on the individual patent, jurisdiction, terminal disclaimers, and pediatric or regulatory adjustments. The commercial conclusion is clear: Stalevo 150 is a post-exclusivity product in the U.S. market.
What patents protect Stalevo 150?
The original protection strategy covered the active ingredients, the combination, therapeutic use, and manufacturing or formulation aspects. Those rights were more important during the product's launch and early commercialization than they are today.
U.S. patent and Orange Book position
The principal U.S. patent risks for Stalevo 150 were:
- Combination-product patents covering levodopa, carbidopa, and entacapone.
- Entacapone composition-of-matter and use patents.
- Method-of-treatment patents directed to reducing motor fluctuations.
- Potential formulation or dosage-regimen claims.
The FDA Orange Book remains the relevant source for patents listed against approved U.S. products and for the status of generic applications. [3] Stalevo 150 does not have the current patent profile of a protected specialty product. Generic applicants have had access to the abbreviated new drug application pathway, subject to applicable patent certifications and regulatory requirements.
How strong is the Stalevo 150 patent estate?
The estate is commercially weak by current branded-pharmaceutical standards because:
- Core exclusivity has expired or no longer prevents broad generic substitution.
- The active ingredients are established small molecules.
- The tablet does not depend on a complex device or delivery platform.
- Clinical substitution is relatively straightforward for patients already receiving the same components.
- Generic applicants can use the same active-ingredient combination rather than reproduce a novel mechanism.
Residual risk can remain for narrow formulation, manufacturing, or method-of-use claims, but those claims are unlikely to restore broad product exclusivity.
What is the FDA regulatory status of Stalevo 150?
Stalevo 150 is an FDA-approved immediate-release oral tablet. The product is approved for Parkinson's disease patients receiving levodopa and carbidopa who have end-of-dose wearing-off. The approved labeling includes dosing restrictions designed to manage levodopa exposure and entacapone administration. [1]
The product's regulatory characteristics limit differentiation:
- It is a conventional oral tablet.
- It does not require a companion diagnostic.
- It is not a controlled substance.
- It has no biosimilar pathway.
- It can be substituted by approved generic equivalents where state substitution rules and payer policies permit.
The principal clinical limitations include dyskinesia, nausea, orthostatic hypotension, hallucinations, diarrhea, urine discoloration, and possible sleep attacks. Entacapone can increase levodopa-related adverse effects by extending dopaminergic exposure. [1]
What generic products compete with Stalevo 150?
The closest generic competitors are fixed-dose carbidopa-levodopa-entacapone tablets. Patients can also receive the same pharmacologic regimen through separate tablets:
- Generic carbidopa-levodopa plus generic entacapone.
- Brand or generic carbidopa-levodopa extended-release products.
- Other adjunctive therapies, including dopamine agonists, MAO-B inhibitors, and amantadine products.
The fixed-dose generic has a cost and convenience advantage over separate tablets. Separate therapy can provide more flexible titration, which is clinically relevant because Parkinson's dosing is often individualized.
| Competitive option |
Main advantage |
Main limitation relative to Stalevo 150 |
| Generic carbidopa-levodopa-entacapone |
Lowest direct substitution cost |
Availability and supply can vary |
| Separate generic carbidopa-levodopa plus entacapone |
Flexible dose adjustment |
More tablets and greater regimen complexity |
| Rytary |
Extended-release levodopa delivery |
Higher cost and different conversion requirements |
| Sinemet or generic immediate-release therapy |
Familiar, inexpensive levodopa backbone |
Does not provide COMT inhibition |
| Opicapone products |
Once-daily COMT inhibition |
Different dosing, pricing, and formulary position |
| Inbrija |
Rescue treatment for off episodes |
Inhaled rescue product, not a replacement maintenance regimen |
What is the financial trajectory of Stalevo 150?
Novartis does not publicly disclose a standalone revenue line for Stalevo 150 in its annual reports. The product is grouped within broader portfolio reporting, and public financial statements do not provide audited global sales by strength. [2]
Its financial trajectory follows a mature off-patent pattern:
Launch and adoption phase
Stalevo gained commercial relevance by combining three established Parkinson's medicines into one tablet. The fixed-dose format addressed adherence and reduced the number of tablets needed for patients experiencing wearing-off.
Post-exclusivity contraction
After generic entry, the product faced:
- Price compression.
- Formulary substitution.
- Declining brand prescriptions.
- Reduced pharmacy reimbursement.
- Conversion to generic combination products.
- Competition from newer extended-release and adjunctive therapies.
The loss of exclusivity likely shifted the product from a growth asset to a maintenance brand. Revenue would be expected to decline faster than prescription volume because generic competition affects both price and branded share.
Mature-brand phase
By the 2020s, Stalevo 150's commercial value was more likely concentrated in:
- Patients stabilized on the branded product.
- Markets with limited generic substitution.
- Countries with weaker generic penetration.
- Patients whose clinicians prefer the original formulation.
- Channel contracts where the brand retains favorable access.
The product can continue generating cash flow after patent expiry, but its gross-to-net economics are usually weaker than during exclusivity. Public data do not support a reliable standalone annual-revenue estimate.
What generic entry risks exist for Stalevo 150?
Generic entry risk is high in the U.S. and other developed markets. The main scenarios are:
| Scenario |
Probability profile |
Effect on Stalevo 150 |
| Additional approved generic suppliers |
High in a mature market |
More price pressure and lower brand share |
| Single-source or constrained generic supply |
Possible |
Temporary brand retention or price stability |
| Payer-mandated generic substitution |
High |
Rapid branded prescription erosion |
| Clinical substitution with separate components |
High |
Reduces dependence on the fixed-dose brand |
| Generic shortage |
Episodic |
Can temporarily support branded demand |
| New branded COMT inhibitor |
Moderate |
May reduce use of entacapone-based regimens |
Generic risk is not limited to direct fixed-dose equivalents. A physician can replace Stalevo 150 with separate generic tablets, which creates a broader substitution pool.
Are there Paragraph IV challenges against Stalevo 150?
Paragraph IV litigation was most relevant during the period when listed patents could block or delay generic approval. Stalevo's current commercial exposure indicates that any central patent barriers have been overcome, expired, settled, or become non-blocking.
A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. Under the Hatch-Waxman Act, a first-filed Paragraph IV applicant can receive 180 days of generic exclusivity if statutory conditions are met. [4] For a mature product such as Stalevo 150, the business importance of historical Paragraph IV filings is lower than the current number of approved generic suppliers and actual substitution rates.
No current litigation record should be inferred solely from the existence of historical patent challenges. Patent disputes must be checked against the relevant federal docket and FDA Orange Book status.
What patent litigation and settlement agreements affect Stalevo 150?
The main litigation risk historically involved generic applicants challenging Novartis-associated patents covering the Stalevo combination or its components. Patent settlements in pharmaceutical cases can include delayed launch dates, licenses, supply arrangements, or other commercial terms. The existence and terms of a settlement cannot be treated as current exclusivity once the relevant patents have expired.
Stalevo 150 is not known as a current high-value patent-litigation asset. Its litigation significance is limited compared with products that have:
- Active composition-of-matter patents.
- Multiple listed formulation patents.
- Patent-term extensions.
- REMS-linked distribution barriers.
- Device or manufacturing complexity.
- High annual branded sales.
How does Stalevo 150 compare with competing Parkinson's drugs?
Stalevo's principal differentiation is convenience, not a unique pharmacologic mechanism. Entacapone extends levodopa exposure, but the same therapeutic objective can be pursued with separate drugs or newer COMT inhibitors.
| Product or class |
Role in Parkinson's treatment |
Competitive position |
| Stalevo 150 |
Maintenance levodopa plus COMT inhibition |
Mature combination brand |
| Generic carbidopa-levodopa-entacapone |
Direct substitute |
Strongest price competitor |
| Rytary |
Extended-release levodopa |
Differentiated release profile |
| Opicapone |
Once-daily COMT inhibitor |
Competes for adjunctive COMT use |
| Safinamide and rasagiline |
MAO-B inhibition |
Alternative adjunctive strategies |
| Inbrija |
Rescue treatment for off episodes |
Complementary rather than direct |
| Duopa |
Continuous intestinal levodopa infusion |
Advanced therapy for severe fluctuations |
| Apomorphine products |
Rescue or advanced therapy |
Used in selected off-episode patients |
The largest structural threat is low-cost generic substitution, while the largest clinical threat is migration to extended-release, once-daily adjunctive, rescue, or infusion-based therapies.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are modest compared with complex biologics or modified-release delivery systems. Stalevo 150 requires control of:
- Three active pharmaceutical ingredients.
- Dose uniformity across a multi-ingredient tablet.
- Stability and impurity profiles.
- Bioequivalence to the reference product.
- Consistent entacapone and levodopa content.
- Supply-chain reliability for all three ingredients.
The main operational risk is not reverse engineering. It is supply continuity. A shortage of any one active ingredient can disrupt production of the finished combination. Generic manufacturers also face the need to demonstrate bioequivalence across a fixed-dose product with multiple actives.
Geographic IP protection is limited as a commercial barrier because core U.S. exclusivity has ended. Market access varies by country based on national patent status, generic approval, reimbursement, procurement rules, and local substitution practices.
What is the commercial outlook for Stalevo 150?
Stalevo 150 is a mature, post-exclusivity Parkinson's product with a declining branded revenue profile and limited ability to regain pricing power. Its residual value comes from brand familiarity, physician continuity, patient stability, and markets where generic substitution is incomplete.
The product is unlikely to drive material growth for Novartis. Its strategic value is more consistent with portfolio maintenance, supply continuity, and residual cash generation. Generic manufacturers have the stronger volume and pricing position, while newer branded therapies compete for patients whose disease progression creates more complex motor fluctuations.
Key Takeaways
- Stalevo 150 contains carbidopa 37.5 mg, levodopa 150 mg, and entacapone 200 mg.
- The FDA approved the product in 2003 for Parkinson's disease patients with end-of-dose wearing-off.
- Core U.S. exclusivity has ended, and generic competition is established.
- The product has no biosimilar risk because it is a small-molecule oral tablet.
- Direct competition comes from generic carbidopa-levodopa-entacapone and separate generic component therapy.
- Novartis does not report Stalevo 150 revenue separately.
- Brand revenue is expected to follow a mature post-patent trajectory: lower volume share, lower price, and residual demand in selected channels.
- Current patent strength is limited, with no broad exclusivity barrier comparable to a newly launched branded drug.
- The main commercial risks are generic substitution, formulary pressure, supply disruptions, and migration to newer Parkinson's regimens.
FAQs
Is Stalevo 150 still available?
Stalevo 150 remains an approved product, but availability varies by market, wholesaler, pharmacy, and supply conditions. Generic fixed-dose and separate-component alternatives are widely relevant.
Is there a generic for Stalevo 150?
Yes. Generic versions of the carbidopa-levodopa-entacapone combination have competed with the branded product, subject to country-specific approval and availability.
What is the difference between Stalevo 150 and Sinemet?
Stalevo 150 contains carbidopa, levodopa, and entacapone. Sinemet contains carbidopa and levodopa only. Stalevo adds COMT inhibition through entacapone to extend levodopa activity.
Is Stalevo 150 protected by an active U.S. patent?
The principal commercial exclusivity protecting Stalevo 150 has ended. Narrow patent issues may depend on a specific listed patent, jurisdiction, or formulation claim, but the product does not have broad current U.S. exclusivity.
Does Stalevo 150 have a biosimilar competitor?
No. Biosimilars apply to biological products. Stalevo 150 is a small-molecule oral tablet and is subject to generic-drug regulation instead.
References
- U.S. Food and Drug Administration. (2003). Stalevo prescribing information and Drugs@FDA approval record.
- Novartis AG. (2023). Annual report 2023. Basel, Switzerland: Novartis.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
